Skip to content
Featured on Startup Fame

Isomorphic Labs lands $5bn at $50bn valuation to push AI drugs into trials

Alphabet-backed Isomorphic Labs just raised $5 billion in a Series C round led by Greenoaks and Sequoia Capital. The deal values the AI drug-discovery firm at $50 billion and will bankroll its first clinical trials plus an expansion into biologics.

Editor, Lazyfounder

Published 3 min read
Isomorphic Labs lands $5bn at $50bn valuation to push AI drugs into trials
Image: The Next Web via source

30 SEC SUMMARY

  • Isomorphic Labs secured $5 billion in a Series C round, pushing its valuation to $50 billion.
  • Greenoaks and Sequoia Capital led the round, which drew new investors like Andreessen Horowitz.
  • The cash will speed up clinical trials and let the company design biologics alongside small-molecule drugs.
  • Eli Lilly, Novartis and Johnson & Johnson are already running more than 20 joint drug programmes with Isomorphic.

$5 billion Series C closes

Isomorphic Labs, the Alphabet-backed drug discovery company founded by DeepMind CEO Demis Hassabis, closed a $5 billion Series C round. Greenoaks and Sequoia Capital co-led the deal, and existing investors—Alphabet, Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund—added follow-on cash. Andreessen Horowitz and other new backers joined, swelling the round past its original target.

$50 billion valuation and next steps

The cash infusion values Isomorphic at roughly $50 billion, making this one of the largest AI-biotech rounds ever. That number reflects how investors now link more computing power directly to better drug candidates.

Money raised will rush the company’s first clinical trials forward and let it design large-molecule biologics alongside its existing small-molecule pipeline. Early cancer and immune-system programmes built with IsoDDE, the company’s AI engine, are already showing positive preclinical results.

Big Pharma partnerships and clinical timeline

Isomorphic has more than 20 drug programmes running with partners Eli Lilly, Novartis and Johnson & Johnson. These collaborations prove pharma is ready to treat AI-designed molecules as real pipeline assets, even though regulators have yet to approve the first one.

Hassabis told reporters the company remains on schedule for regulatory filings. While he did not move the expected 2026 start date for first-in-human trials, he promised fresh updates in 2027.

Why investors bought in—and where the chips will come from

Sequoia partner Konstantine Buhler said the fund backed Isomorphic because the company has proven its models follow clear scaling laws: feed them more data and computing power, and they design better drugs.

Hassabis also put worries about AI-chip shortages to rest. Google’s in-house tensor chips guarantee the compute pipeline Isomorphic needs, regardless of market shifts after Jensen Huang’s exit from Nvidia.

From AlphaFold to clinical trials

Isomorphic launched in 2021 on the strength of Google DeepMind’s AlphaFold protein-structure model. Today the company keeps offices in London, Cambridge (Massachusetts) and Lausanne.

The $5 billion round arrived just eighteen months after a $2.1 billion raise in May 2026, mirroring the torrid pace of capital flowing into AI-powered drug discovery.

Key takeaways

  • The $50 billion valuation sets the highest marker yet for AI-powered drug discovery startups, showing investors now tie scaling laws directly to compute-driven outcomes.
  • Pharma giants Eli Lilly, Novartis and Johnson & Johnson are already treating AI-designed molecules as pipeline assets—before any regulator has approved one.
  • Alphabet’s compute, DeepMind’s algorithms and Isomorphic’s twenty clinical-stage programmes combined into a single oversubscribed asset, lifting the bar for any competitor looking for serious funding.

Sources

  1. The Next Web · 2026-11-17
    Isomorphic Labs raises $5bn from Sequoia and Greenoaks for AI drug design

This story is an original summary drafted with AI by Lazyfounder from the reporting listed above and checked by automated validation. Facts are attributed to their original publishers; sections marked as analysis are Lazyfounder's. Where a source is in another language, facts were machine-translated and quotations are reported, not reproduced. Read the original coverage via the links, and see our AI policy and corrections policy.

About the author

Editor, Lazyfounder

Tarun Mottlia edits LazyFounders, covering Indian startups, funding rounds, AI and product launches. Every story on the site is AI-assisted and checked against its cited sources before publication.

More stories by Tarun Mottlia

Get the LazyFounder Brief

Startup, funding and AI news in a five-minute read. Join the early-access list.

Lazy Founder - Powered by Blogy.in

Contact us

Have a story tip, correction or partnership idea?

Write to us at tarun.kumar@blogy.in or talk to the founder directly. We read every message.

Contact us